Endocarditis medical therapy

Jump to navigation Jump to search

Endocarditis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Infective Endocarditis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease

Diagnosis and Follow-up

Medical Therapy

Intervention

Case Studies

Case #1

Endocarditis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Endocarditis medical therapy

CDC onEndocarditis medical therapy

Endocarditis medical therapy in the news

Blogs on Endocarditis medical therapy

to Hospitals Treating Endocarditis medical therapy

Risk calculators and risk factors for Endocarditis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Ahmed Zaghw, M.D. [3]

Overview

Blood cultures should be drawn prior to instituting antibiotics to identify the etiologic agent and to determine its antimicrobial susceptibility. Older antibiotics such as penicillin G, ampicillin, nafcillin, cefazolin, gentamycin, ceftriaxone, rifampin and vancomycin are the mainstays of therapy.

Timing of Initiation of Antibiotics

Antibiotic therapy for subacute or indolent disease can be delayed until results of blood cultures are known; in fulminant infection or valvular dysfunction requiring urgent surgical intervention, begin empirical antibiotic therapy promptly after blood cultures have been obtained.

Duration of Antibiotic Therapy

The duration for native valve endocarditis is often 4 weeks. For prosthetic valve endocarditis (including the presence of a valve ring), treatment should be continued for 6 to 8 weeks. For each infective agent, the preferred antimicrobial agent, dose, and duration is listed below.

Empirical Antibiotic Therapy

  • Antibiotic therapy for subacute hemodynamically stable disease, and in those who have received antibiotics recently can be delayed waiting for the results of blood cultures, as this delay allows an additional blood cultures without the confounding effect of empiric treatment, which is very important in determining the causing pathogens.[1]
  • On the other hand, the rapid progression of acute cases necessitate the start of empirical treatment antibiotic therapy once the blood cultures have been collected.
  • Empirical therapy is needed for all likely pathogens, certain antibiotic agents, including aminoglycosides, is preferably avoided for its toxic effects.
  • Clinical course of infection beside the epidemiological features should be considered upon selecting empirical treatment regimen.
  • Consultation with an infectious disease specialist for the selection of one of the antibiotic regimens is recommended (see therapy for culture-negative endocarditis). [2]

Treatment Based Upon Infectious Agent[3]

Streptococci

Native Valve Endocarditis Caused by Viridans Group Streptococci and Streptococcus bovis

Viridans Group Streptococci and Streptococcus bovis Highly Penicillin-Susceptible
Native Valve Endocarditis Caused by Highly Penicillin-Susceptible
Viridans Group Streptococci and Streptococcus bovis
Preferred Regimen ( 4 wks )
Adult dose
Penicillin G sodium † 12–18 million U/24 h IV either continuously or in 4-6 equally divided doses x 4 Wks
OR
Ceftriaxone sodium 2 g/24 h IV/IM in 1 dose x 4 Wks
Pediatric dose ₳
Penicillin G sodium 200 000 U/kg q24h IV either continuously or in 4-6 equally divided doses x 4 Wks
OR
Ceftriaxone 100 mg/kg q24 h IV/IM in 1 dose x 4 Wks
Alternative Regimen ( 2 wks )
Adult dose
Penicillin G sodium‡ 12–18 million U/24 h IV either continuously or in 6 equally divided doses x 2 Wks
OR
Ceftriaxone sodium 2 g/24 h IV/IM in 1 dose x 2 Wks
PLUS
Gentamicin sulfate ฿ 3 mg/Kg per 24h 1 dose x 2 Wks\
Pediatric dose
Penicillin G sodium 200 000 U/kg q24h IV in 4-6 equally divided doses x 2 Wks
OR
Ceftriaxone 100 mg/kg q24 h IV/IM in 1 dose x 2 Wks
PLUS
Gentamicin sulfate 3 mg/Kg per 24h 1 dose or 3 equally divided doses x 2 Wks
Alternative Regimen
Adult dose
Vancomycin hydrochloride ¶ 15 mg/kg q12h IV x 4 Wks
Doses should not to exceed 2 g/24 h unless concentrations in serum are inappropriately low
Pediatric dose
Vancomycin hydrochloride 40 mg/kg per 24 h IV in 2–3 equally divided doses
Minimum inhibitory concentration ≤ 0.12 μg/mL.
† Preferred in most patients >65 y or patients with impairment of 8th cranial nerve function or renal function.
₳ Pediatric dose should not exceed that of a normal adult.
‡ 2-wk regimen not intended for patients with known cardiac or extracardiac abscess or for those with creatinine clearance of <20 mL/min, impaired 8th cranial nerve function, or Abiotrophia, Granulicatella, or Gemella spp infection; gentamicin dosage should be adjusted to achieve peak serum concentration of 3-4 μg/mL and trough serum concentration of >1 μg/mL when 3 divided doses are used; nomogram used for single daily dosing.
¶ Vancomycin therapy recommended only for patients unable to tolerate penicillin or ceftriaxone; vancomycin dosage should be adjusted to obtain peak (1 h after infusion completed) serum concentration of 30–45 μg/mL and a trough concentration range of 10–15 μg/mL
฿ Other potentially nephrotoxic drugs (eg, nonsteroidal antiinflammatory drugs) should be used with caution in patients receiving gentamicin therapy. Although it is preferred that gentamicin (3 mg/kg) be given as a single daily dose to adult patients with endocarditis due to viridans group streptococci, as a second option, gentamicin can be administered daily in 3 equally divided doses.
Viridans Group Streptococci and Streptococcus bovis Relatively Penicillin Resistant (MIC >0.12 μg/mL- ≤ 0.5 μg/mL)
Native Valve Endocarditis Caused by Strains of Viridans Group Streptococci and Streptococcus bovis Relatively Resistant to Penicillin (MIC >0.12 μg/mL- ≤ 0.5 μg/mL))
Preferred Regimen
Adult dose
Penicillin G sodium 24 million U/24 h IV either continuously or in 4–6 equally divided doses x 4 wks
OR
Ceftriaxone 2 g/24 h IV/IM in 1 dose x 4 wks
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 1 dose x 2 wks
Pediatric dose
Penicillin G sodium 300 000 U/kg per 24 h IV in 4–6 equally divided doses
OR
Ceftriaxone 100 mg/kg per 24 h IV/IM in 1 dose
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 1 dose or equally divided doses
Alternative Regimen
Adult dose
Vancomycin hydrochloride 30 mg/kg per 24 h IV in 2 equally divided doses x 4 wks
Pediatric dose
Vancomycin hydrochloride 40 mg/kg per 24 h IV or in 2 or 3 equally divided doses

Prosthetic Valves Endocarditis Caused by Viridans Group Streptococci and Streptococcus Bovis

Viridans Group Streptococci and Streptococcus bovis Penicillin-susceptible strain (MIC ≤ 0.12 μg/mL)
Penicillin-susceptible strain (MIC ≤ 0.12 g/mL)
Preferred Regimen
Adult dose
Penicillin G sodium † 24 million U/24 h IV either continuously or in 4–6 equally divided doses x 6 wks
OR
Ceftriaxone 2 g/24 h IV/IM in 1 dose x 6 wks
WITH OR WITHOUT
Gentamicin sulfate ‡ 3 mg/kg per 24 h IV/IM in 1 dose x 2 wks
Pediatric dose
Penicillin G sodium 300 000 U/kg per 24 h IV in 4–6 equally divided doses
OR
Ceftriaxone 100 mg/kg IV/IM once daily
WITH OR WITHOUT
Gentamicin 3 mg/kg per 24 h IV/IM, in 1 dose or 3 equally divided doses
Alternative Regimen
Adult dose
Vancomycin hydrochloride 30 mg/kg per 24 h IV in 2 equally divided doses x 6 wks
Pediatric dose
40 mg/kg per 24 h IV or in 2 or 3 equally divided doses
  • Dosages recommended are for patients with normal renal function.
† Penicillin or ceftriaxone together with gentamicin has not demonstrated superior cure rates compared with monotherapy with penicillin or ceftriaxone for patients with highly susceptible strain; gentamicin therapy should not be administered to patients with creatinine clearance of <30 mL/min.
‡ Although it is preferred that gentamicin (3 mg/kg) be given as a single daily dose to adult patients with endocarditis due to viridans group streptococci, as a second option, gentamicin can be administered daily in 3 equally divided doses.
Viridans Group Streptococci and Streptococcus bovis Penicillin relatively or fully resistant strain (MIC >0.12 μg/mL)
Penicillin relatively or fully resistant strain (MIC >0.12 >μg/mL))
Preferred Regimen
Adult dose
Penicillin G sodium 24 million U/24 h IV either continuously or in 4–6 equally divided doses x 6 wks
OR
Ceftriaxone 2 g/24 h IV/IM in 1 dose x 6 wks
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 1 dose x 6 wks
Pediatric dose
Penicillin G sodium 300 000 U/kg per 24 h IV in 4–6 equally divided doses
Alternative Regimen
Adult dose
Vancomycin hydrochloride 30 mg/kg per 24 h IV in 2 equally divided doses x 6 wks
Pediatric dose
Vancomycin hydrochloride 40 mg/kg per 24 h IV or in 2 or 3 equally divided doses
Viridans Group Streptococci and Streptococcus bovis Relatively Penicillin-Resistant Streptococci, MIC 0.2–0.5 µg/ml
Relatively Penicillin-Resistant Streptococci, MIC 0.2–0.5 µg/ml
Preferred Regimen
Adult dose
Penicillin G potassium 24 million U/24 h IV either continuously or in 4–6 equally divided doses X 4 Wks
OR
Ceftriaxone 2 g/24 h IV/IM in 1 dose
AND
Gentamicin 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hr X 2 Wks
Pediatric dose
Penicillin G potassium 300 000 U/24 h IV in 4–6 equally divided doses X 4 Wks
OR
Ceftriaxone 100 mg/kg per 24 h IV/IM in 1 dose
AND
Gentamicin 3 mg/kg per 24 h IV/IM in 1 dose or 3 equally divided doses X 2 Wks
Relatively Penicillin-Resistant Streptococci, (MIC > 0.5 µg/ml)
Relatively Penicillin-Resistant Streptococci,
MIC > 0.5 µg/ml, consider Enterococcal regimen
Preferred Regimen
Adult dose
Penicillin G potassium 24 million U/24 h IV either continuously or in 4–6 equally divided doses x 4 Wks
PLUS
Gentamicin 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hr x 2 Wks
Pediatric dose
Penicillin G potassium 24 million U/24 h IV either continuously or in 4–6 equally divided doses x 4 Wks
PLUS
Gentamicin 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hr x 2 Wks
Unable to tolerate Penicillin or Ceftriaxone
Unable to tolerate Aqueous crystalline penicillin G sodium or Ceftriaxone
Preferred Regimen
Adult dose
Vancomycin 30 mg/kg per 24 h IV in 2 equally divided doses not to exceed 2 g/24 h, unless serum concentrations are inappropriately low
Pediatric dose
Vancomycin 40 mg/kg 24 h in 2 or 3 equally divided doses X 4 Wks

Enterococci

Native valve or prosthetic valve enterococcal endocarditis requires combination therapy with two antibiotics as the following:[2]

Enterococci Strains Susceptible to Penicillin, Gentamicin, and Vancomycin
Enterococci Strains Susceptible to Penicillin, Gentamicin, and Vancomycin
Preferred Regimen
Adult dose
Ampicillin 12 g/24 h I.V.in 6 equally divided doses x 4–6 Wks
OR
Penicillin G sodium 18–30 million U. I.V. daily in 6 equally divided doses x 4–6 Wks
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 4-6 Wks
Alternative Regimen
Vancomycin 30 mg/kg I.V. daily in 2 equally divided doses x 6 Wks
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks
Pediatric dose
Ampicillin 300 mg/kg per 24 h IV in 4–6 equally divided doses; X 4–6 Wks
OR
Penicillin G sodium 300 000 U/kg per 24 h IV in 4–6 equally divided doses X 4–6 Wks
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses X 4-6 Wks
OR (in penicillin hypersensitivity)
Vancomycin 30 mg/kg I.V. daily in divided doses q. 12 hour X 4–6 Wks
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses X 4-6 Wks
Enterococci Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin
Enterococci Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin
Preferred Regimen
Adult dose
Ampicillin 12 g/24 h I.V.in 6 equally divided doses x 4–6 Wks
OR
Penicillin G sodium 24 million U. I.V. continuously or in 6 equally divided doses x 4–6 Wks
PLUS
Streptomycin sulfate 15 mg/kg per 24 h IV/IM in 2 equally divided doses x 4-6 Wks
Pediatric dose
Ampicillin 300 mg/kg per 24 h IV in 4–6 equally divided doses; x 4–6 Wks
OR
Penicillin G sodium 300 000 U/kg per 24 h IV in 4–6 equally divided doses x 4–6 Wks
PLUS
Streptomycin sulfate 20–30 mg/kg per 24 h IV/IM in 2 equally divided doses
Alternative Regimen
Vancomycin 30 mg/kg I.V. daily in 2 equally divided doses x 6 Wks
PLUS
Streptomycin sulfate 15 mg/kg per 24 h IV/IM in 2 equally divided doses x 4-6 Wks
Pediatric dose
Vancomycin 40 mg/kg per 24 h IV in 2 or 3 equally divided doses X 4–6 Wks
PLUS
Streptomycin sulfate 20–30 mg/kg per 24 h IV/IM in 2 equally divided doses
  • Native valve: 4-wk therapy recommended for patients with symptoms of illness < 3 months.
  • 6-wk therapy recommended for patients with symptoms >3 months.
  • Prosthetic valve or other prosthetic cardiac material: minimum of 6 wk of therapy recommended.
  • Vancomycin therapy recommended only for patients unable to tolerate penicillin or ampicillin.
Enterococci Strains Resistant to Penicillin and Susceptible to Aminoglycoside and Vancomycin
β-Lactamase–producing strain
Preferred Regimen
Adult dose
Ampicillin-sulbactam 12 g/24 h IV in 4 equally divided doses x 6 Wks
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks
Pediatric dose
Ampicillin-sulbactam 300 mg/kg per 24 h IV in 4 equally divided doses x 6 Wks
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks
Alternative Regimen
Vancomycin hydrochloride 30 mg/kg per 24 h IV in 2 equally divided doses x 6 Wks
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks
Pediatric dose
Vancomycin hydrochloride 40 mg/kg per 24 h in 2 or 3 equally divided doses
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks
Intrinsic penicillin resistance
Adult dose
Vancomycin hydrochloride 30 mg/kg per 24 h IV in 2 equally divided doses x 6 Wks
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks
Pediatric dose
Vancomycin hydrochloride 40 mg/kg per 24 h in 2 or 3 equally divided doses
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks
Enterococci Strains Resistant to Penicillin, Aminoglycoside, and Vancomycin
E faecium
Adult dose
Linezolid 1200 mg/24 h IV/PO in 2 equally divided doses x ≥8 Wks
OR
Quinupristin-dalfopristin 22.5 mg/kg per 24 h IV in 3 equally divided doses x ≥ 8 Wks
Pediatric dose
Linezolid 30 mg/kg per 24 h IV/PO in 3 equally divided doses ≥8 Wks
OR
Quinupristin-dalfopristin 22.5 mg/kg per 24 h IV in 3 equally divided doses ≥8 Wks
E faecalis
Adult dose
Preferred Regimen
Imipenem/cilastatin 2 g/24 h IV in 4 equally divided doses x ≥8 Wks
PLUS
Ampicillin sodium 12 g/24 h IV in 6 equally divided doses x ≥ 8 Wks
Pediatric dose
Imipenem/cilastatin 60–100 mg/kg per 24 h IV in 4 equally divided doses x ≥8 Wks
PLUS
Ampicillin sodium 300 mg/kg per 24

h IV in 4–6 equally divided doses x ≥ 8 Wks

Alternative Regimen
Adult dose
Ceftriaxone sodium 4 g/24 h IV/IM in 2 equally divided doses x ≥8 Wks
PLUS
Ampicillin sodium 12 g/24 h IV in 6 equally divided doses x ≥ 8 Wks
Pediatric dose
Ceftriaxone sodium 100 mg/kg per 24 h IV/IM in 2 equally divided doses x ≥8 Wks
PLUS
Ampicillin sodium 300 mg/kg per 24 h IV in 4–6 equally divided doses x ≥ 8 Wks
  • Patients with endocarditis caused by these strains should be treated in consultation with an infectious diseases specialist.
  • Cardiac valve replacement may be necessary for bacteriologic cure.
  • Cure with antimicrobial therapy alone may be < 50%
  • Severe, usually reversible thrombocytopenia may occur with use of linezolid, especially after 2 wk of therapy.
  • Quinupristin-dalfopristin only effective against E faecium and can cause severe myalgias, which may require discontinuation of therapy
  • Only small no. of patients have reportedly been treated with imipenem/cilastatin-ampicillin or ceftriaxone + ampicillin.

Staphylococci

Native Valve Endocarditis caused by Staphylococci in the Absence of Prosthetic Material

Staphylococci (Methicillin Susceptible) in the Absence of Prosthetic Material
Staphylococci (Methicillin Susceptible) in the Absence of Prosthetic Material
Preferred Regimen
Adult dose
Nafcillin or Oxacillin † 12 g I.V. daily in equally divided doses x 6 Wks
PLUS (optional)
Gentamicin sulfate ‡ 3 mg/kg per 24 h IV/IM in 2-3 equally divided doses x 3-5 days
Altenative Regimen( in non anaphylactoid Penicillin hypersensitivity)
Cefazolin 6 g/ 24 h I.V. in 3 divided doses x 6 wks
PLUS (optional)
Gentamicin 3 mg/kg per 24 h IV/IM in 2-3 equally divided doses x 3-5 days
Pediatrics dose
Nafcillin or oxacillin 200 mg/kg per 24 h IV in 4–6 equally divided doses x 4-6 wks
OR ( in non anaphylactoid Penicillin hypersensitivity)
Cefazolin 100 mg/kg per 24 h IV in 3 equally divided doses x 4-6 wks
AND (optional)
Gentamicin 3 mg/kg per 24 h IV/IM in 3 equally divided doses
† Penicillin G 24 million U/24 h IV in 4 to 6 equally divided doses may be used in place of nafcillin or oxacillin if strain is penicillin susceptible (MIC ≤ 0.1 μg/mL) and does not produce β-lactamase.
‡ Gentamicin should be administered in close temporal proximity to vancomycin, nafcillin, or oxacillin dosing.
Staphylococci (Methicillin-resistant) with Penicillin G Anaphylactoid Hypersensitivity in the Absence of Prosthetic Material
Staphylococci (Methicillin-resistant) in the Absence of Prosthetic Material
(in anaphylactoid Penicillin hypersensitivity)
Preferred Regimen
Adult dose
Vancomycin 30 mg/kg per 24 h IV in 2 equally divided doses x 6 wks
Adjust vancomycin dosage to achieve 1-h serum concentration of 30–45 > g/mL and trough concentration of 10–15 >g/mL
Pediatrics dose
Vancomycin 40 mg/kg per 24 h IV in 2 or 3 equally divided doses x 6 wks

Prosthetic Valves Endocarditis or Other Prosthetic Material Caused by Staphylococci

Oxacillin-susceptible strains in the Presence of Prosthetic Material
Oxacillin-susceptible strains
Adult dose
Nafcillin or oxacillin 2 g q4h IV x ≥6 weeks
PLUS
Rifampin 300 mg q8h IV/PO x ≥6 weeks
PLUS
Gentamicin 3 mg/kg per 24 h IV/IM in 2 or 3 equally divided doses x 2 weeks
Pediatric dose
Nafcillin or oxacillin 200 mg/kg per 24 h IV in 4–6 equally divided doses
PLUS
Rifampin 20 mg/kg per 24 h IV/PO in 3 equally divided doses
PLUS
Gentamicin 1 mg/kg q8h IV/IM
Oxacillin-resistant strains in the Presence of Prosthetic Material
Oxacillin-resistant strains
Adult dose
Vancomycin 15 mg/kg q12h x ≥6 Wks
PLUS
Rifampin 300 mg q8h IV/PO x ≥6 Wks
PLUS
Gentamicin 3 mg/kg per 24 h IV/IM in 2 or 3 equally divided doses x 2 wks
Pediatric dose
Vancomycin 40 mg/kg per 24 h IV in 2-3 equally divided doses x ≥6 wks
PLUS
Rifampin 20 mg/kg per 24 h IV/PO in 3 equally divided doses x ≥6 wks
PLUS
Gentamicin 1 mg/kg q8h IV/IM x 2 Wks

HACEK Organisms

HACEK organisms are more indolent and the infection is less complicated. [2]

Therapy for Both Native and Prosthetic Valve Endocarditis Caused by HACEK Microorganisms
Adult dose
Ceftriaxone sodium † 2 g/24 h IV/IM in 1 dose x 4 weeks
OR
Ampicillin- sulbactam ‡ 12 g/24 h IV in 4 equally divided doses x 4 weeks
OR
Ciprofloxacin ঠ500 mg q12h PO or 400 mg q12h IV x 4 weeks
Pediatric dose
Ceftriaxone 100 mg/kg per 24 h IV/IM once daily
OR
Ampicillin- sulbactam 300 mg/kg per 24 h IV divided into 4 or 6 equally divided doses
OR
Ciprofloxacin 10-15 mg/kg q12h IV/PO
  • HACEK: Haemophilus parainfluenzae, H aphrophilus, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae.
† Patients should be informed that IM injection of ceftriaxone is painful.
‡ Dosage recommended for patients with normal renal function.
¶ Fluoroquinolones are highly active in vitro against HACEK microorganisms. Published data on use of fluoroquinolone therapy for endocarditis caused by HACEK are minimal.

Culture Negative Endocarditis

  • Clinical course of infection beside the epidemiological features should be considered upon selecting treatment regimen.
  • Patients should be divided into 2 groups:[2]

Patients Who Received Antibiotic Therapy Before the Blood Culture

  • Patients with acute clinical presentations with native valve infection: coverage of S. aureus should be followed as detailed in proven staphylococcal disease.
  • Patients with subacute presentation: antibiotic coverage for S. aureus, viridians group streptococci, and enterococci should be considered.
  • Antibiotics for HACEK group of organism also should be considered.
  • Symptomatic patients with prosthetic valve and culture negative infection within 1 year of valve replacement should receive vancomycin to cover the oxacillin-resistant staphylococci.
  • Symptomatic patients with prosthetic valve and culture negative infection within 2 months of valve replacement should also receive cefepime for gram negative bacilli coverage.
  • Symptomatic patients with prosthetic valve more than 1 year, the most likely causing organisms are oxacillin-susceptible staphylococci, viridians group streptococci, and enterococci. Antibiotic coverage for those organisms should be continued for at least 6 weeks.

Patients with Culture-Negative Endocarditis and Suspected Infection with Uncommon Endocarditis Pathogens

  • Examples of these pathogens include Bartonella species, Chlamydia species, Coxiella burnetii, Brucella species, Legionella species, Tropheryma whippleii, and non-Candida fungi.
  • Antibiotic therapy for these pathogens should include aminoglycosides for at least 2 weeks.
  • Therapeutic regimens for Bartonella endocarditis based on the epidemiological risk and high index of suspicion.

Native Valve Culture Negative Endocarditis

Native valve
Adult dose
Ampicillin-Sulbactam 3 g q6h IV x 4–6 wks
PLUS
Gentamicin sulfate 1 mg per kg q8h IV/IM x 4–6 wks
OR
Vancomycin 15 mg per kg q12h IV x 4–6 wks
PLUS
Gentamicin sulfate 1 mg per kg q8h IV/IM x 4–6 wks
PLUS
Ciprofloxacin 500 mg q12h PO or 320 mg q12h IV x 4–6 wks
Pediatric dose
Ampicillin-Sulbactam300 mg per kg per 24 h IV in 4–6 equally divided doses
PLUS
Gentamicin 1 mg per kg q8h IV/IM x 4–6 wks
OR
Vancomycin 32 mg per kg per 24 h in 2 or 3 equally divided doses x 4–6 wks
PLUS
Gentamicin sulfate 1 mg per kg q8h IV/IM x 4–6 wks
PLUS
Ciprofloxacin 10-15 mg per kg q12h IV/PO x 4–6 wks

Prosthetic Valve Culture Negative Endocarditis

Prosthetic valve (early, ≤ 1y)
Adult dose
Vancomycin 15 mg per kg q12h IV x 4-6 wks
PLUS
Gentamicin sulfate 1 mg per kg q8h IV/IM x 2wks
PLUS
Cefepime 2 g q8h IV x 6 wks
PLUS
Rifampin 300 mg q8h PO/IV x 6 wks
Pediatric dose
Vancomycin 15 mg per kg q12h IV x 4-6 wks
PLUS
Gentamicin 1 mg per kg q8h IV/IM x 2 wks
PLUS
Cefepime 50 mg q8h IV x 6 wks
PLUS
Rifampin 20 mg per kg per 24 h PO/IV in 3 equally divided doses x 6 wks
Prosthetic valve (late—greater than 1 y) (same regimens as for native valve endocarditis with addition of rifampin)
Ampicillin-Sulbactam 3 g q6h IV x 4–6 wks
PLUS
Gentamicin sulfate 1 mg per kg q8h IV/IM x 4–6 wks
PLUS
Rifampin 300 mg q8h PO/IV x 6 wks
OR
Vancomycin 15 mg per kg q12h IV x 4–6 wks
PLUS
Gentamicin sulfate 1 mg per kg q8h IV/IM x 4–6 wks
PLUS
Ciprofloxacin 500 mg q12h PO or 320 mg q12h IV x 4–6 wks
PLUS
Rifampin 300 mg q8h PO/IV x 6 wks

Bartonella Culture Negative Endocarditis

Suspected Bartonella, (culture negative)
Adult dose
Ceftriaxone sodium 2 g per 24 h IV/IM in 1 dose x 6 wks
PLUS
Gentamicin sulfate 1 mg per kg q8h IV/IM x 2 wks
WITH / WITHOUT
Doxycycline 100 mg per kg q12h IV/PO x 6 wks
Pediatrics dose
Ceftriaxone sodium 100 mg/kg per 24 h IV/IM once daily x 6 wks
PLUS
Gentamicin sulfate 1 mg per kg q8h IV/IM x 2 wks
WITH / WITHOUT
Doxycycline 2–4 mg per kg per 24 h IV/PO in 2 equally divided doses
Documented Bartonella, (culture positive)
Adult dose
Doxycycline 100 mg q12h IV or PO x 6 wks
PLUS
Gentamicin sulfate 1 mg per kg q8h IV/IM x 2 wks
Pediatrics dose
Doxycycline 2–4 mg per kg per 24 h IV/PO in 2 equally divided doses
PLUS
Gentamicin 1 mg per kg q8h IV/IM

References

  1. Braunwald, Eugene; Bonow, Robert O. (2012). Braunwald's heart disease : a textbook of cardiovascular medicin. Philadelphia: Saunders. ISBN 978-1-4377-2708-1.
  2. 2.0 2.1 2.2 2.3 Baddour, LM.; Wilson, WR.; Bayer, AS.; Fowler, VG.; Bolger, AF.; Levison, ME.; Ferrieri, P.; Gerber, MA.; Tani, LY. (2005). "Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): e394–434. doi:10.1161/CIRCULATIONAHA.105.165564. PMID 15956145. Unknown parameter |month= ignored (help)
  3. Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F., Levison Matthew E., Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong David C., Steckelberg James M., Baltimore Robert S., Shulman Stanford T., Burns Jane C., Falace Donald A., Newburger Jane W., Pallasch Thomas J., Takahashi Masato, Taubert Kathryn A. (2005). "Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association-Executive Summary: Endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): 3167–84. PMID 15956145.

Template:WH Template:WS